Pliant Therapeutics Inc.
03/30/2026 | Press release | Distributed by Public on 03/30/2026 15:42
Material Event (Form 8-K)
Item 8.01 Other Events
As previously disclosed, on March 30, 2026, Pliant Therapeutics, Inc. (the "Company") entered into a Sales Agreement, or the 2026 Sales Agreement, with Leerink Partners LLC, as sales agent, with respect to an at-the-market offering program to sell shares of the Company's common stock from time to time through the sales agent. Pursuant to the "at the market offering" prospectus, the Company may offer and sell shares of its common stock having an aggregate offering price of up to $50.0 million.
Effective as of March 27, 2026, the Company terminated the Controlled Equity Offering℠ Sales Agreement dated July 2, 2021, or the 2021 Sales Agreement, with Cantor Fitzgerald & Co. The Company is not subject to any termination penalties related to the termination of the 2021 Sales Agreement. Prior to termination, the Company had not sold any shares of its common stock pursuant to the 2021 Sales Agreement. As a result of the termination of the 2021 Sales Agreement, the Company will not offer or sell any shares of its common stock under the 2021 Sales Agreement.
A copy of the 2021 Sales Agreement was filed as Exhibit 1.2 to the registration statement on Form S-3ASR (File No. 333-257684) filed by the Company on July 2, 2021. The description of the 2021 Sales Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the copy of the 2021 Sales Agreement filed as Exhibit 1.2 to the registration statement on Form S-3ASR (File No. 333-257684) filed by the Company on July 2, 2021.
Pliant Therapeutics Inc. published this content on March 30, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 30, 2026 at 21:44 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]